Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Autolus Therapeutics (AUTL) EBT: 2016-2024

Historic EBT for Autolus Therapeutics (AUTL) over the last 9 years, with Dec 2024 value amounting to -$219.1 million.

  • Autolus Therapeutics' EBT rose 4.25% to -$78.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$220.2 million, marking a year-over-year increase of 18.51%. This contributed to the annual value of -$219.1 million for FY2024, which is 5.15% down from last year.
  • Latest data reveals that Autolus Therapeutics reported EBT of -$219.1 million as of FY2024, which was down 5.15% from -$208.4 million recorded in FY2023.
  • Autolus Therapeutics' EBT's 5-year high stood at -$142.0 million during FY2021, with a 5-year trough of -$219.1 million in FY2024.
  • Over the past 3 years, Autolus Therapeutics' median EBT value was -$208.4 million (recorded in 2023), while the average stood at -$192.0 million.
  • Its EBT has fluctuated over the past 5 years, first spiked by 33.47% in 2021, then crashed by 40.27% in 2023.
  • Autolus Therapeutics' EBT (Yearly) stood at -$213.5 million in 2020, then surged by 33.47% to -$142.0 million in 2021, then dropped by 4.60% to -$148.6 million in 2022, then plummeted by 40.27% to -$208.4 million in 2023, then decreased by 5.15% to -$219.1 million in 2024.